Brentuximab vedotin is a CD30-directed antibody-drug conjugate used to treat various types of lymphoma. Brentuximab vedotin, also known as Adcetris, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin’s lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment [rx].
The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [rx].
Adcetris has also been previously approved by the FDA to treat Hodgkin’s lymphoma after relapse, Hodgkin’s lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after the failure of other treatment regimens [rx].
Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin’s lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [rx].
The ECHELON-1 study results demonstrated the superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [rx].
Mechanism of action
Brentuximab vedotin is composed of 3 parts: a chimeric human-murine IgG1 that selectively targets CD30, monomethyl auristatin E (MMAE), which is a microtubule-disrupting agent, and a protease-susceptible linker that links the antibody and MMAE. The IgG1 antibody enables Brentuximab vedotin to target tumor cells expressing CD30 on their surface. Following this Brentuximab vedotin enters the cell. Once inside, the linker is cleaved releasing MMAE which binds and disrupts the microtubule network.[rx]
The antibody component of this drug is a chimeric IgG1 directed against CD30. The small molecule, MMAE, is a microtubule-disrupting particle. MMAE is covalently attached to the antibody by a linker. Data suggest that the anticancer activity of Adcertris is due to the binding of the ADC to CD30-expressing cells, followed by internalization of the ADC-CD30 complex, and the subsequent release of MMAE by proteolytic cleavage. The binding of MMAE to tubulin disrupts the microtubule network within the cell, inducing cell cycle arrest and apoptosis of the malignant cells
Indications
- Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin’s lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or progression. Finally, it may be used in the treatment of adult patients with cHL who have previously failed either auto-HSCT or at least two prior multi-agent chemotherapy regimens if they are not candidates for auto-HSCT.[rx]
- Brentuximab vedotin is additionally indicated in the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL), or other CD30-expressing peripheral T-cell lymphomas (PTCL), in combination with cyclophosphamide, doxorubicin, and prednisone. It may also be used as monotherapy in sALCL after the therapeutic failure of a least one prior multi-agent chemotherapy regimen.[rx]
- Brentuximab vedotin is also indicated in the treatment of primary cutaneous large anaplastic large cell lymphoma, or CD30-expressing mycosis fungoides, who have received prior systemic therapy.[rx]
- CD30-expressing Mycosis Fungoides (MF)
- Classical Hodgkin’s Lymphoma
- Peripheral T Cell Lymphoma (PTCL)
- Primary Cutaneous Anaplastic Large Cell Lymphoma
- Systemic Anaplastic Large Cell Lymphoma
- Stage 3 Classical Hodgkin’s Lymphoma
Brentuximab vedotin is an anti-neoplastic agent used in the treatment of Hodgkin’s lymphoma [PMID:25796459] and systemic anaplastic large-cell lymphoma. Several clinical trials are evaluating the combination of brentuximab vedotin with immune checkpoint inhibitors, to assess any synergistic effects as a result of dual targeting. Checkpoint inhibitors being investigated in this way include nivolumab and pembrolizumab (both anti-PD-1), and ipilimumab (anti-CTLA4). Brentuximab vedotin + pembrolizumab (NCT02684292) and brentuximab vedotin + nivolumab (NCT03138499) are both Phase 3 studies in patients with relapsed/refractory classical Hodgkin’s lymphoma. Expanded approvals:In November 2017, the FDA approved brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, following review of results from the Phase 3 ALCANZA trial (NCT01578499) . In March 2018, the FDA approved the use of brentuximab vedotin for the treatment of patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. This expansion was based on results from the ECHELON-1 clinical trial (NCT01712490). November 2018 saw further expansion of approval for the use of brentuximab vedotin plus chemotherapy for adult patients who are newly diagnosed with CD30-expressing peripheral T-cell lymphomas.
Use in Cancer
Brentuximab vedotin is approved for use in adults to treat:
- Anaplastic large cell lymphoma. Brentuximab vedotin is used in:
- Patients whose cancer is systemic (affects the whole body) and has not gotten better after treatment with combination chemotherapy.
- Patients whose cancer has not been treated. is given with cyclophosphamide, doxorubicin hydrochloride, and prednisone.
- Cutaneous anaplastic large cell lymphoma is primary. Brentuximab vedotin is used in patients who have received other systemic therapy.
- Hodgkin lymphoma. Brentuximab vedotin is used:
- After an autologous stem cell transplant (ASCT) patients who have a high risk that cancer will recur (come back) or get worse.
- In patients whose cancer has not gotten better after an ASCT. Brentuximab vedotin is also used in patients whose cancer has not gotten better after at least two treatments with combination chemotherapy and who cannot receive an ASCT.
- With chemotherapy in patients with stage III or stage IV Hodgkin lymphoma whose cancer has not been treated.
- Mycosis fungoides (a type of cutaneous T-cell lymphoma). Brentuximab vedotin is used in patients whose cancer has the CD30 protein and who have received other systemic therapy.
- Peripheral T-cell lymphoma that has the CD30 protein. Brentuximab vedotin is given with cyclophosphamide, doxorubicin hydrochloride, and prednisone.
Brentuximab vedotin is also being studied in the treatment of other conditions and types of cancer.
Contraindications
- a bad infection
- anemia
- decreased blood platelets
- low levels of a type of white blood cell called neutrophils
- a painful condition that affects the nerves in the legs and arms called peripheral neuropathy
- a type of inflammation of the lung called interstitial pneumonitis
- pregnancy
- a patient who is producing milk and breastfeeding
- a rupture in the wall of the stomach or intestine
- progressive multifocal leukoencephalopathy, a type of brain infection
- chronic kidney disease stage 4 (severe)
- chronic kidney disease stage 5 (failure)
- kidney disease with likely reduction in kidney function
- Child-Pugh class B liver impairment
- Child-Pugh class C liver impairment
Dosage
Strengths: 50 mg
Hodgkin’s Disease
- Previously Untreated State III or IV Classical Hodgkin Lymphoma: 1.2 mg/kg (maximum 120 mg) IV over 30 minutes in combination with chemotherapy; administer every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity
- Classical Hodgkin Lymphoma Consolidation: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; initiate therapy within 4 to 6 weeks post-auto-HSCT or upon recovery from auto-HSCT; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
- Relapsed Classical Hodgkin Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity
- Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma or DC30-Expressing Mycosis Fungoides (MF): 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
- Relapsed Systemic Anaplastic Large Cell Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity
- The dose for patients weighing more than 100 kg should be calculated based on a weight of 100 kg.
- In patients with previously untreated Stage III or IV cHL who are treated with this drug plus doxorubicin/ vinblastine/dacarbazine (AVD), administer G-CSF beginning with Cycle 1.
- For previously untreated Stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy
- For adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation
- For adults with cHL after the failure of auto-HSCT or after failure of at least 2 prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates
- For adults with systemic anaplastic large cell lymphoma (sALCL) after the failure of at least one prior multi-agent chemotherapy regimen
- For adults with pcALCL or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy
Mycosis Fungoides
- Previously Untreated Stage III or IV Classical Hodgkin Lymphoma: 1.2 mg/kg (maximum 120 mg) IV over 30 minutes in combination with chemotherapy; administer every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity
- Classical Hodgkin Lymphoma Consolidation: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; initiate therapy within 4 to 6 weeks post-auto-HSCT or upon recovery from auto-HSCT; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
- Relapsed Classical Hodgkin Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity
- Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma or DC30-Expressing Mycosis Fungoides (MF): 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
- Relapsed Systemic Anaplastic Large Cell Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity
- The dose for patients weighing more than 100 kg should be calculated based on a weight of 100 kg.
- In patients with previously untreated Stage III or IV cHL who are treated with this drug plus doxorubicin/ vinblastine/dacarbazine (AVD), administer G-CSF beginning with Cycle 1.
- For previously untreated Stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy
- For adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation
- For adults with cHL after the failure of auto-HSCT or after failure of at least 2 prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates
- For adults with systemic anaplastic large cell lymphoma (sALCL) after the failure of at least one prior multi-agent chemotherapy regimen
- For adults with pcALCL or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy
Lymphoma
- Previously Untreated Stage III or IV Classical Hodgkin Lymphoma: 1.2 mg/kg (maximum 120 mg) IV over 30 minutes in combination with chemotherapy; administer every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity
- Classical Hodgkin Lymphoma Consolidation: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; initiate therapy within 4 to 6 weeks post-auto-HSCT or upon recovery from auto-HSCT; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
- Relapsed Classical Hodgkin Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity
- Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma or DC30-Expressing Mycosis Fungoides (MF): 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
- Relapsed Systemic Anaplastic Large Cell Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity
- The dose for patients weighing more than 100 kg should be calculated based on a weight of 100 kg.
- In patients with previously untreated Stage III or IV cHL who are treated with this drug plus doxorubicin/ vinblastine/dacarbazine (AVD), administer G-CSF beginning with Cycle 1.
- For previously untreated Stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy
- For adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation
- For adults with cHL after the failure of auto-HSCT or after failure of at least 2 prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates
- For adults with systemic anaplastic large cell lymphoma (sALCL) after the failure of at least one prior multi-agent chemotherapy regimen
- For adults with pcALCL or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy
Liver Dose Adjustments
Mild hepatic impairment (Child-Pugh A)
- If the recommended dose is 1.2 mg/kg (maximum 120 mg) IV over 30 minutes every 2 weeks, reduce the dose to 0.9 mg/kg (maximum 90 mg) IV over 30 minutes every 2 weeks; the dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg
- If the recommended dose is 1.8 mg/kg (maximum 180 mg) IV over 30 minutes every 3 weeks, reduce the dose to 1.2 mg/kg (maximum 120 mg) IV over 30 minutes every 3 weeks; the dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg
- Moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment: Not recommended.
Dose Adjustments
Peripheral Neuropathy/Neutropenia:
GRADE 3 OR 4:
- If the recommended dose is 1.2 mg/kg (maximum 120 mg) IV over 30 minutes every 2 weeks, administer G-CSF prophylaxis for subsequent cycles for patients not receiving primary G-CSF prophylaxis.
- If the recommended dose is 1.8 mg/kg (maximum 180 mg) IV over 30 minutes every 3 weeks, hold dosing until improvement to baseline or Grade 2 or lower and consider G-CSF prophylaxis for subsequent cycles; for recurrent Grade 4 despite G-CSF prophylaxis consider discontinuing therapy or reduce the dose to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks.
Side Effects
The Most Common
- constipation
- mouth sores
- decreased appetite
- weight loss
- tiredness
- dizziness
- weakness
- difficulty falling asleep or staying asleep
- anxiety
- dry skin
- hair loss
- night sweats
- joint, bone, muscle, back, arm, or leg pain
- muscle spasms
More Common
- unusual bleeding or bruising
- numbness, burning, or tingling in the hands, arms, feet, or legs
- muscle weakness
- peeling or blistering skin
- hives
- rash
- itching
- nausea
- vomiting
- diarrhea
- cough or shortness of breath
- decreased urination
- swelling of the hands, feet, ankles, or lower legs
- difficult, painful, or frequent urination
- fever, chills, cough, or other signs of infection
- ongoing pain that begins in the stomach area but may spread to the back
- pale skin
- yellowing of the skin or eyes
- pain or discomfort in the right upper stomach area
- dark urine
- clay-colored bowel movements
- stomach pain
- unusual bleeding or bruising
- black and tarry stools
- red blood in stools
Rare
- numbness, weakness, burning pain, tingly feeling, or loss of feeling in your arms or legs;
- sudden chest pain or discomfort, wheezing, dry cough, feeling short of breath;
- pain or burning when you urinate;
- high blood sugar–increased thirst, increased urination, dry mouth, fruity breath odor;
- ketoacidosis (too much acid in the blood)- nausea, vomiting, stomach pain, confusion, unusual drowsiness, or trouble breathing; or
- low blood cell counts–fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath;
- signs of tumor cell breakdown–confusion, weakness, muscle cramps, nausea, vomiting, fast or slow heart rate, decreased urination, tingling in your hands and feet or around your mouth;
- pancreatitis–severe pain in your upper stomach spreading to your back, nausea and vomiting;
- liver problems–loss of appetite, stomach pain (upper right side), tiredness, dark urine, jaundice (yellowing of the skin or eyes); or
- stomach problems–severe constipation, new or worsening stomach pain, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.
Interaction
DRUG | INTERACTION |
---|---|
Abametapir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Abametapir. |
Abatacept | The metabolism of Brentuximab vedotin can be increased when combined with Abatacept. |
Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Brentuximab vedotin. |
Abemaciclib | The metabolism of Abemaciclib can be decreased when combined with Brentuximab vedotin. |
Abrocitinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Abrocitinib. |
Acalabrutinib | The metabolism of Brentuximab vedotin can be decreased when combined with Acalabrutinib. |
Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with Brentuximab vedotin. |
Acetaminophen | The metabolism of Brentuximab vedotin can be increased when combined with Acetaminophen. |
Acetazolamide | The metabolism of Brentuximab vedotin can be decreased when combined with Acetazolamide. |
Adalimumab | The metabolism of Brentuximab vedotin can be increased when combined with Adalimumab. |
Adenovirus | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Brentuximab vedotin. |
Aducanumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Aducanumab. |
Afatinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Afatinib. |
Albendazole | The metabolism of Brentuximab vedotin can be decreased when combined with Albendazole. |
Aldesleukin | The metabolism of Brentuximab vedotin can be decreased when combined with Aldesleukin. |
Alectinib | The metabolism of Alectinib can be decreased when combined with Brentuximab vedotin. |
Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Brentuximab vedotin. |
Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brentuximab vedotin. |
Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with Brentuximab vedotin. |
Alirocumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Alirocumab. |
Allogeneic processed | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Brentuximab vedotin. |
Alpelisib | The metabolism of Brentuximab vedotin can be increased when combined with Alpelisib. |
Alprazolam | The metabolism of Alprazolam can be decreased when combined with Brentuximab vedotin. |
Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Brentuximab vedotin. |
Ambrisentan | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ambrisentan. |
Aminoglutethimide | The metabolism of Brentuximab vedotin can be increased when combined with Aminoglutethimide. |
Aminophylline | The metabolism of Aminophylline can be decreased when combined with Brentuximab vedotin. |
Amiodarone | The serum concentration of Brentuximab vedotin can be increased when it is combined with Amiodarone. |
Amivantamab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Amivantamab. |
Amobarbital | The metabolism of Brentuximab vedotin can be increased when combined with Amobarbital. |
Amprenavir | The metabolism of Brentuximab vedotin can be decreased when combined with Amprenavir. |
Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Brentuximab vedotin. |
Anakinra | The metabolism of Brentuximab vedotin can be increased when combined with Anakinra. |
Anifrolumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Anifrolumab. |
Ansuvimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ansuvimab. |
Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Brentuximab vedotin. |
Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Brentuximab vedotin. |
Antilymphocyte | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Antilymphocyte immunoglobulin (horse). |
Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brentuximab vedotin. |
Apalutamide | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Apalutamide. |
Apixaban | The serum concentration of Brentuximab vedotin can be increased when it is combined with Apixaban. |
Apremilast | The metabolism of Brentuximab vedotin can be increased when combined with Apremilast. |
Aprepitant | The metabolism of Brentuximab vedotin can be decreased when combined with Aprepitant. |
Aripiprazole | The metabolism of Aripiprazole can be decreased when combined with Brentuximab vedotin. |
Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be decreased when combined with Brentuximab vedotin. |
Armodafinil | The metabolism of Brentuximab vedotin can be increased when combined with Armodafinil. |
Arsenic trioxide | The serum concentration of Brentuximab vedotin can be increased when it is combined with Arsenic trioxide. |
Articaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Articaine. |
Asciminib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Asciminib. |
Asfotase alfa | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Asfotase alfa. |
Astemizole | The metabolism of Brentuximab vedotin can be decreased when combined with Astemizole. |
COVID-19 Vaccine | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Brentuximab vedotin. |
Asunaprevir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Asunaprevir. |
Atazanavir | The metabolism of Brentuximab vedotin can be decreased when combined with Atazanavir. |
Atezolizumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atezolizumab. |
Atoltivimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atoltivimab. |
Atorvastatin | The metabolism of Atorvastatin can be decreased when combined with Brentuximab vedotin. |
Avacopan | The metabolism of Brentuximab vedotin can be decreased when combined with Avacopan. |
Avanafil | The serum concentration of Avanafil can be increased when it is combined with Brentuximab vedotin. |
Avatrombopag | The serum concentration of Brentuximab vedotin can be increased when it is combined with Avatrombopag. |
Avelumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Avelumab. |
Axitinib | The metabolism of Axitinib can be decreased when combined with Brentuximab vedotin. |
Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Brentuximab vedotin. |
Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Brentuximab vedotin. |
Azithromycin | The metabolism of Brentuximab vedotin can be decreased when combined with Azithromycin. |
Bacillus | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Brentuximab vedotin. |
Bacillus | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Brentuximab vedotin. |
Bacillus | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Brentuximab vedotin. |
Bamlanivimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bamlanivimab. |
Baricitinib | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Baricitinib. |
Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Brentuximab vedotin. |
BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Brentuximab vedotin. |
Bebtelovimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bebtelovimab. |
Beclomethasone | The metabolism of Brentuximab vedotin can be increased when combined with Beclomethasone dipropionate. |
Belantamab mafodotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Belantamab mafodotin. |
Belatacept | The risk or severity of adverse effects can be increased when Belatacept is combined with Brentuximab vedotin. |
Belimumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Belimumab. |
Belinostat | The risk or severity of adverse effects can be increased when Belinostat is combined with Brentuximab vedotin. |
Belumosudil | The serum concentration of Brentuximab vedotin can be increased when it is combined with Belumosudil. |
Belzutifan | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Belzutifan. |
Bendamustine | The risk or severity of adverse effects can be increased when Bendamustine is combined with Brentuximab vedotin. |
Benralizumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Benralizumab. |
Benzocaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Benzocaine. |
Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Benzyl alcohol. |
Berotralstat | The serum concentration of Brentuximab vedotin can be increased when it is combined with Berotralstat. |
Besilesomab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Besilesomab. |
Betamethasone | The metabolism of Brentuximab vedotin can be increased when combined with Betamethasone. |
Betamethasone phosphate | The metabolism of Brentuximab vedotin can be increased when combined with Betamethasone phosphate. |
Betrixaban | The serum concentration of Brentuximab vedotin can be increased when it is combined with Betrixaban. |
Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brentuximab vedotin. |
Bexarotene | The metabolism of Brentuximab vedotin can be increased when combined with Bexarotene. |
Bezlotoxumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bezlotoxumab. |
Bicalutamide | The metabolism of Brentuximab vedotin can be decreased when combined with Bicalutamide. |
Bifonazole | The metabolism of Brentuximab vedotin can be decreased when combined with Bifonazole. |
Bimekizumab | The metabolism of Brentuximab vedotin can be increased when combined with Bimekizumab. |
Bisoprolol | The serum concentration of Brentuximab vedotin can be increased when it is combined with Bisoprolol. |
Bleomycin | The risk or severity of pulmonary toxicity can be increased when Brentuximab vedotin is combined with Bleomycin. |
Blinatumomab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Blinatumomab. |
Boceprevir | The metabolism of Brentuximab vedotin can be decreased when combined with Boceprevir. |
Bortezomib | The metabolism of Bortezomib can be decreased when combined with Brentuximab vedotin. |
Bosentan | The metabolism of Brentuximab vedotin can be increased when combined with Bosentan. |
Bosutinib | The metabolism of Brentuximab vedotin can be decreased when combined with Bosutinib. |
Brigatinib | The metabolism of Brigatinib can be decreased when combined with Brentuximab vedotin. |
Brodalumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Brodalumab. |
Brolucizumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Brolucizumab. |
Budesonide | The metabolism of Brentuximab vedotin can be increased when combined with Budesonide. |
Bupivacaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Bupivacaine. |
Buprenorphine | The metabolism of Brentuximab vedotin can be decreased when combined with Buprenorphine. |
Burosumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Burosumab. |
Busulfan | The metabolism of Busulfan can be decreased when combined with Brentuximab vedotin. |
Butacaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Butacaine. |
Butalbital | The metabolism of Brentuximab vedotin can be increased when combined with Butalbital. |
Butamben | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Butamben. |
Cabazitaxel | The metabolism of Cabazitaxel can be decreased when combined with Brentuximab vedotin. |
Cabergoline | The metabolism of Cabergoline can be decreased when combined with Brentuximab vedotin. |
Calcitriol | The metabolism of Brentuximab vedotin can be increased when combined with Calcitriol. |
Canagliflozin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin. |
Canakinumab | The metabolism of Brentuximab vedotin can be increased when combined with Canakinumab. |
Candicidin | The metabolism of Brentuximab vedotin can be decreased when combined with Candicidin. |
Cannabidiol | The metabolism of Brentuximab vedotin can be decreased when combined with Cannabidiol. |
Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Brentuximab vedotin. |
Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Brentuximab vedotin. |
Capmatinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Capmatinib. |
Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brentuximab vedotin. |
Capsaicin | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Capsaicin. |
Carbamazepine | The metabolism of Brentuximab vedotin can be increased when combined with Carbamazepine. |
Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Brentuximab vedotin. |
Carfilzomib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Carfilzomib. |
Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Brentuximab vedotin. |
Carvedilol | The serum concentration of Brentuximab vedotin can be increased when it is combined with Carvedilol. |
Casirivimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Casirivimab. |
Catumaxomab | The risk or severity of adverse effects can be increased when Catumaxomab is combined with Brentuximab vedotin. |
Cefradine | The metabolism of Brentuximab vedotin can be increased when combined with Cefradine. |
Cemiplimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Cemiplimab. |
Cenobamate | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Cenobamate. |
Cephalexin | The metabolism of Brentuximab vedotin can be decreased when combined with Cephalexin. |
Ceritinib | The metabolism of Brentuximab vedotin can be decreased when combined with Ceritinib. |
Cerivastatin | The metabolism of Brentuximab vedotin can be increased when combined with Cerivastatin. |
Certolizumab pegol | The metabolism of Brentuximab vedotin can be increased when combined with Certolizumab pegol. |
Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Brentuximab vedotin. |
Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Brentuximab vedotin. |
Chloramphenicol | The metabolism of Brentuximab vedotin can be decreased when combined with Chloramphenicol. |
Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Chloroprocaine. |
Chlorpromazine | The metabolism of Brentuximab vedotin can be increased when combined with Chlorpromazine. |
Ciclesonide | The risk or severity of adverse effects can be increased when Ciclesonide is combined with Brentuximab vedotin. |
Cilgavimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Cilgavimab. |
Cilostazol | The metabolism of Cilostazol can be decreased when combined with Brentuximab vedotin. |
Cimetidine | The metabolism of Brentuximab vedotin can be decreased when combined with Cimetidine. |
Cinchocaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Cinchocaine. |
Ciprofloxacin | The metabolism of Brentuximab vedotin can be decreased when combined with Ciprofloxacin. |
Cisapride | The metabolism of Brentuximab vedotin can be decreased when combined with Cisapride. |
Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Brentuximab vedotin. |
Citalopram | The metabolism of Brentuximab vedotin can be decreased when combined with Citalopram. |
Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Brentuximab vedotin. |
Clarithromycin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Clarithromycin. |
Clevidipine | The metabolism of Brentuximab vedotin can be increased when combined with Clevidipine. |
Clobazam | The metabolism of Brentuximab vedotin can be increased when combined with Clobazam. |
Clobetasol propionate | The metabolism of Brentuximab vedotin can be increased when combined with Clobetasol propionate. |
Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Brentuximab vedotin. |
Clofazimine | The serum concentration of Brentuximab vedotin can be increased when it is combined with Clofazimine. |
Clofibrate | The metabolism of Brentuximab vedotin can be increased when combined with Clofibrate. |
Clomifene | The serum concentration of Brentuximab vedotin can be increased when it is combined with Clomifene. |
Clomipramine | The metabolism of Clomipramine can be decreased when combined with Brentuximab vedotin. |
Clonidine | The metabolism of Clonidine can be decreased when combined with Brentuximab vedotin. |
Clostridium | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brentuximab vedotin. |
Clozapine | The metabolism of Brentuximab vedotin can be increased when combined with Clozapine. |
Cobicistat | The serum concentration of Brentuximab vedotin can be increased when it is combined with Cobicistat. |
Cobimetinib | The metabolism of Cobimetinib can be decreased when combined with Brentuximab vedotin. |
Cocaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Cocaine. |
Colchicine | The metabolism of Colchicine can be decreased when combined with Brentuximab vedotin. |
Conivaptan | The serum concentration of Brentuximab vedotin can be increased when it is combined with Conivaptan. |
Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Brentuximab vedotin. |
Copanlisib | The metabolism of Copanlisib can be decreased when combined with Brentuximab vedotin. |
Corticotropin | The metabolism of Brentuximab vedotin can be increased when combined with Corticotropin. |
Cortisone acetate | The metabolism of Brentuximab vedotin can be increased when combined with Cortisone acetate. |
Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brentuximab vedotin. |
Crizotinib | The metabolism of Brentuximab vedotin can be decreased when combined with Crizotinib. |
Curcumin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Curcumin. |
Cyclophosphamide | The metabolism of Brentuximab vedotin can be increased when combined with Cyclophosphamide. |
Cyclosporine | Brentuximab vedotin may increase the immunosuppressive activities of Cyclosporine. |
Cyproterone acetate | The metabolism of Brentuximab vedotin can be decreased when combined with Cyproterone acetate. |
Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Brentuximab vedotin. |
Dabigatran etexilate | The serum concentration of Brentuximab vedotin can be increased when it is combined with Dabigatran etexilate. |
Dabrafenib | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib. |
Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Brentuximab vedotin. |
Daclatasvir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Daclatasvir. |
Dacomitinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Dacomitinib. |
Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Brentuximab vedotin. |
Dalfopristin | The metabolism of Brentuximab vedotin can be decreased when combined with Dalfopristin. |
Danazol | The metabolism of Brentuximab vedotin can be decreased when combined with Danazol. |
Daptomycin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Daptomycin. |
Daratumumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Daratumumab. |
Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brentuximab vedotin. |
Darolutamide | The serum concentration of Brentuximab vedotin can be increased when it is combined with Darolutamide. |
Darunavir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Darunavir. |
Dasabuvir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Dasabuvir. |
Dasatinib | The metabolism of Brentuximab vedotin can be decreased when combined with Dasatinib. |
Daunorubicin | The metabolism of Brentuximab vedotin can be decreased when combined with Daunorubicin. |
Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Brentuximab vedotin. |
Deflazacort | The metabolism of Brentuximab vedotin can be increased when combined with Deflazacort. |
Delavirdine | The metabolism of Brentuximab vedotin can be decreased when combined with Delavirdine. |
Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Brentuximab vedotin. |
Desipramine | The metabolism of Brentuximab vedotin can be decreased when combined with Desipramine. |
Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Brentuximab vedotin. |
Desvenlafaxine | The metabolism of Brentuximab vedotin can be decreased when combined with Desvenlafaxine. |
Deucravacitinib | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Deucravacitinib. |
Dexamethasone | The metabolism of Brentuximab vedotin can be increased when combined with Dexamethasone. |
Dexamethasone acetate | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Dexamethasone acetate. |
Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Brentuximab vedotin. |
Dextropropoxyphene | The metabolism of Brentuximab vedotin can be decreased when combined with Dextropropoxyphene. |
Dicloxacillin | The metabolism of Brentuximab vedotin can be increased when combined with Dicloxacillin. |
Dienestrol | Dienestrol may increase the thrombogenic activities of Brentuximab vedotin. |
Diethylstilbestrol | The metabolism of Brentuximab vedotin can be decreased when combined with Diethylstilbestrol. |
Difluocortolone | The metabolism of Brentuximab vedotin can be increased when combined with Difluocortolone. |
Digitoxin | The metabolism of Digitoxin can be decreased when combined with Brentuximab vedotin. |
Digoxin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Digoxin. |
Digoxin Immune | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brentuximab vedotin. |
Dihydroergocornine | The metabolism of Brentuximab vedotin can be decreased when combined with Dihydroergocornine. |
Dihydroergocristine | The metabolism of Brentuximab vedotin can be decreased when combined with Dihydroergocristine. |
Dihydroergotamine | The metabolism of Brentuximab vedotin can be decreased when combined with Dihydroergotamine. |
Diltiazem | The metabolism of Brentuximab vedotin can be decreased when combined with Diltiazem. |
Dimethyl fumarate | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dimethyl fumarate. |
Dimethyl sulfoxide | The metabolism of Brentuximab vedotin can be decreased when combined with Dimethyl sulfoxide. |
Dinutuximab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dinutuximab. |
Diosmin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Diosmin. |
Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Diphenhydramine. |
Diroximel fumarate | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Diroximel fumarate. |
Docetaxel | The metabolism of Brentuximab vedotin can be decreased when combined with Docetaxel. |
Dofetilide | The metabolism of Dofetilide can be decreased when combined with Brentuximab vedotin. |
Dolutegravir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Dolutegravir. |
Dostarlimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dostarlimab. |
Doxazosin | The metabolism of Brentuximab vedotin can be decreased when combined with Doxazosin. |
Doxorubicin | The metabolism of Brentuximab vedotin can be decreased when combined with Doxorubicin. |
Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Brentuximab vedotin. |
Dronedarone | The serum concentration of Brentuximab vedotin can be increased when it is combined with Dronedarone. |
Drospirenone | The metabolism of Brentuximab vedotin can be decreased when combined with Drospirenone. |
Dulaglutide | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dulaglutide. |
Dupilumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dupilumab. |
Durvalumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Durvalumab. |
Duvelisib | The metabolism of Brentuximab vedotin can be decreased when combined with Duvelisib. |
Dyclonine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Dyclonine. |
Ebastine | The metabolism of Brentuximab vedotin can be decreased when combined with Ebastine. |
Ebola Zaire | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Brentuximab vedotin. |
Echinacea | The metabolism of Brentuximab vedotin can be increased when combined with Echinacea. |
Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Brentuximab vedotin. |
Edoxaban | The serum concentration of Brentuximab vedotin can be increased when it is combined with Edoxaban. |
Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Brentuximab vedotin. |
Efavirenz | The metabolism of Brentuximab vedotin can be decreased when combined with Efavirenz. |
Eflapegrastim | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eflapegrastim. |
Eftrenonacog alfa | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eftrenonacog alfa. |
Elagolix | The serum concentration of Brentuximab vedotin can be increased when it is combined with Elagolix. |
Elbasvir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Elbasvir. |
Elexacaftor | The metabolism of Brentuximab vedotin can be decreased when combined with Elexacaftor. |
Eliglustat | The metabolism of Eliglustat can be decreased when combined with Brentuximab vedotin. |
Elotuzumab | The risk or severity of adverse effects can be increased when Elotuzumab is combined with Brentuximab vedotin. |
Elvitegravir | The metabolism of Brentuximab vedotin can be decreased when combined with Elvitegravir. |
Emapalumab | The metabolism of Brentuximab vedotin can be increased when combined with Emapalumab. |
Emicizumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Emicizumab. |
Enasidenib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Enasidenib. |
Enfortumab vedotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Enfortumab vedotin. |
Entrectinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Entrectinib. |
Enzalutamide | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Enzalutamide. |
Epinephrine | The metabolism of Brentuximab vedotin can be decreased when combined with Epinephrine. |
Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Brentuximab vedotin. |
Eptinezumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eptinezumab. |
Erdafitinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Erdafitinib. |
Erenumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Erenumab. |
Ergotamine | The metabolism of Brentuximab vedotin can be decreased when combined with Ergotamine. |
Eribulin | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eribulin. |
Erlotinib | The metabolism of Brentuximab vedotin can be decreased when combined with Erlotinib. |
Ertugliflozin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ertugliflozin. |
Erythromycin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Erythromycin. |
Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Brentuximab vedotin. |
Esketamine | The metabolism of Brentuximab vedotin can be increased when combined with Esketamine. |
Eslicarbazepine | The metabolism of Brentuximab vedotin can be increased when combined with Eslicarbazepine. |
Eslicarbazepine acetate | The metabolism of Brentuximab vedotin can be increased when combined with Eslicarbazepine acetate. |
Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Brentuximab vedotin. |
Estetrol | The metabolism of Brentuximab vedotin can be decreased when combined with Estetrol. |
Estradiol | Estradiol may increase the thrombogenic activities of Brentuximab vedotin. |
Estradiol acetate | The metabolism of Brentuximab vedotin can be increased when combined with Estradiol acetate. |
Estradiol benzoate | The metabolism of Brentuximab vedotin can be increased when combined with Estradiol benzoate. |
Estradiol cypionate | The metabolism of Brentuximab vedotin can be increased when combined with Estradiol cypionate. |
Estradiol dienanthate | The metabolism of Brentuximab vedotin can be increased when combined with Estradiol dienanthate. |
Estradiol valerate | The metabolism of Brentuximab vedotin can be increased when combined with Estradiol valerate. |
Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Brentuximab vedotin. |
Estriol | Estriol may increase the thrombogenic activities of Brentuximab vedotin. |
Estrone | Estrone may increase the thrombogenic activities of Brentuximab vedotin. |
Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Brentuximab vedotin. |
Eszopiclone | The metabolism of Eszopiclone can be decreased when combined with Brentuximab vedotin. |
Etanercept | The metabolism of Brentuximab vedotin can be increased when combined with Etanercept. |
Ethambutol | The metabolism of Brentuximab vedotin can be decreased when combined with Ethambutol. |
Ethanol | The metabolism of Brentuximab vedotin can be increased when combined with Ethanol. |
Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Brentuximab vedotin. |
Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Ethyl chloride. |
Etidocaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Etidocaine. |
Etoposide | The metabolism of Etoposide can be decreased when combined with Brentuximab vedotin. |
Etoricoxib | The metabolism of Brentuximab vedotin can be decreased when combined with Etoricoxib. |
Etravirine | The metabolism of Brentuximab vedotin can be increased when combined with Etravirine. |
Everolimus | The serum concentration of Brentuximab vedotin can be increased when it is combined with Everolimus. |
Evolocumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Evolocumab. |
Fanolesomab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fanolesomab. |
Favipiravir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Favipiravir. |
Fedratinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Fedratinib. |
Felbamate | The metabolism of Brentuximab vedotin can be increased when combined with Felbamate. |
Fenofibrate | The metabolism of Brentuximab vedotin can be decreased when combined with Fenofibrate. |
Fentanyl | The metabolism of Fentanyl can be decreased when combined with Brentuximab vedotin. |
Fexinidazole | The metabolism of Brentuximab vedotin can be decreased when combined with Fexinidazole. |
Fexofenadine | The serum concentration of Brentuximab vedotin can be increased when it is combined with Fexofenadine. |
Filgotinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Filgotinib. |
Finerenone | The serum concentration of Finerenone can be increased when it is combined with Brentuximab vedotin. |
Fingolimod | Brentuximab vedotin may increase the immunosuppressive activities of Fingolimod. |
Flibanserin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Flibanserin. |
Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Brentuximab vedotin. |
Flucloxacillin | The metabolism of Brentuximab vedotin can be increased when combined with Flucloxacillin. |
Fluconazole | The serum concentration of Brentuximab vedotin can be increased when it is combined with Fluconazole. |
Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Brentuximab vedotin. |
Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Brentuximab vedotin. |
Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Brentuximab vedotin. |
Flunisolide | The metabolism of Brentuximab vedotin can be increased when combined with Flunisolide. |
Fluocinolone | The metabolism of Brentuximab vedotin can be increased when combined with Fluocinolone acetonide. |
Fluocinonide | The metabolism of Brentuximab vedotin can be increased when combined with Fluocinonide. |
Fluocortolone | The metabolism of Brentuximab vedotin can be increased when combined with Fluocortolone. |
Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Brentuximab vedotin. |
Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Brentuximab vedotin. |
Fluoxetine | The metabolism of Brentuximab vedotin can be decreased when combined with Fluoxetine. |
Fluprednisolone | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fluprednisolone. |
Fluticasone | The metabolism of Brentuximab vedotin can be increased when combined with Fluticasone. |
Fluticasone furoate | The metabolism of Brentuximab vedotin can be increased when combined with Fluticasone furoate. |
Fluticasone propionate | The metabolism of Brentuximab vedotin can be decreased when combined with Fluticasone propionate. |
Fluvoxamine | The metabolism of Brentuximab vedotin can be decreased when combined with Fluvoxamine. |
Formestane | The metabolism of Brentuximab vedotin can be increased when combined with Formestane. |
Fosamprenavir | The metabolism of Brentuximab vedotin can be decreased when combined with Fosamprenavir. |
Fosaprepitant | The metabolism of Brentuximab vedotin can be increased when combined with Fosaprepitant. |
Fosnetupitant | The metabolism of Brentuximab vedotin can be decreased when combined with Fosnetupitant. |
Fosphenytoin | The metabolism of Brentuximab vedotin can be increased when combined with Fosphenytoin. |
Fostamatinib | The metabolism of Brentuximab vedotin can be decreased when combined with Fostamatinib. |
Fostemsavir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Fostemsavir. |
Fremanezumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fremanezumab. |
Fusidic acid | The metabolism of Brentuximab vedotin can be decreased when combined with Fusidic acid. |
Futibatinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Futibatinib. |
Galcanezumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Galcanezumab. |
Gallium nitrate | The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Brentuximab vedotin. |
Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Brentuximab vedotin. |
Gemtuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brentuximab vedotin. |
Gilteritinib | The metabolism of Brentuximab vedotin can be decreased when combined with Gilteritinib. |
Ginkgo biloba | The metabolism of Brentuximab vedotin can be decreased when combined with Ginkgo biloba. |
Glasdegib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Glasdegib. |
Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Brentuximab vedotin. |
Glecaprevir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Glecaprevir. |
Glyburide | The metabolism of Brentuximab vedotin can be decreased when combined with Glyburide. |
Glycerol | The metabolism of Brentuximab vedotin can be increased when combined with Glycerol phenylbutyrate. |
Golimumab | The metabolism of Brentuximab vedotin can be increased when combined with Golimumab. |
Grazoprevir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Grazoprevir. |
Griseofulvin | The metabolism of Brentuximab vedotin can be increased when combined with Griseofulvin. |
Guselkumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Guselkumab. |
Ipilimumab | The risk or severity of adverse effects can be increased when Ipilimumab is combined with Brentuximab vedotin. |
Irbesartan | The metabolism of Brentuximab vedotin can be decreased when combined with Irbesartan. |
Irinotecan | The metabolism of Irinotecan can be decreased when combined with Brentuximab vedotin. |
Isatuximab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Isatuximab. |
Isavuconazole | The serum concentration of Brentuximab vedotin can be increased when it is combined with Isavuconazole. |
Isavuconazonium | The serum concentration of Brentuximab vedotin can be increased when it is combined with Isavuconazonium. |
Isoniazid | The metabolism of Brentuximab vedotin can be decreased when combined with Isoniazid. |
Isradipine | The metabolism of Brentuximab vedotin can be decreased when combined with Isradipine. |
Istradefylline | The serum concentration of Brentuximab vedotin can be increased when it is combined with Istradefylline. |
Itraconazole | The serum concentration of Brentuximab vedotin can be increased when it is combined with Itraconazole. |
Ivacaftor | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ivacaftor. |
Ivosidenib | The metabolism of Brentuximab vedotin can be increased when combined with Ivosidenib. |
Ixabepilone | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ixabepilone. |
Ixazomib | The metabolism of Ixazomib can be decreased when combined with Brentuximab vedotin. |
Ixekizumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ixekizumab. |
COVID-19 Vaccine | The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Brentuximab vedotin. |
Japanese encephalitis | The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Brentuximab vedotin. |
Ketazolam | The metabolism of Brentuximab vedotin can be decreased when combined with Ketazolam. |
Ketoconazole | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ketoconazole. |
Lacosamide | The metabolism of Brentuximab vedotin can be decreased when combined with Lacosamide. |
Lanadelumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lanadelumab. |
Lanreotide | The metabolism of Brentuximab vedotin can be decreased when combined with Lanreotide. |
Lapatinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Lapatinib. |
Larotrectinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Larotrectinib. |
Lasmiditan | The serum concentration of Brentuximab vedotin can be increased when it is combined with Lasmiditan. |
Ledipasvir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ledipasvir. |
Lefamulin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Lefamulin. |
Leflunomide | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Leflunomide. |
Lemborexant | The serum concentration of Brentuximab vedotin can be increased when it is combined with Lemborexant. |
Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Brentuximab vedotin. |
Lenvatinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Lenvatinib. |
Lesinurad | The metabolism of Brentuximab vedotin can be increased when combined with Lesinurad. |
Letermovir | The metabolism of Brentuximab vedotin can be decreased when combined with Letermovir. |
Levacetylmethadol | The metabolism of Levacetylmethadol can be decreased when combined with Brentuximab vedotin. |
Levamlodipine | The serum concentration of Levamlodipine can be increased when it is combined with Brentuximab vedotin. |
Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Levobupivacaine. |
Levoketoconazole | The serum concentration of Brentuximab vedotin can be increased when it is combined with Levoketoconazole. |
Levothyroxine | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Levothyroxine. |
Lidocaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Lidocaine. |
Linagliptin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Linagliptin. |
Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Brentuximab vedotin. |
Lomitapide | The serum concentration of Brentuximab vedotin can be increased when it is combined with Lomitapide. |
Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Brentuximab vedotin. |
Lonafarnib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Lonafarnib. |
Loncastuximab | The serum concentration of Brentuximab vedotin can be increased when it is combined with Loncastuximab tesirine. |
Loperamide | The serum concentration of Brentuximab vedotin can be increased when it is combined with Loperamide. |
Lopinavir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Lopinavir. |
Lorlatinib | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Lorlatinib. |
Losartan | The metabolism of Brentuximab vedotin can be decreased when combined with Losartan. |
Lovastatin | The metabolism of Lovastatin can be decreased when combined with Brentuximab vedotin. |
Loxapine | The serum concentration of Brentuximab vedotin can be increased when it is combined with Loxapine. |
Lumacaftor | The serum concentration of Brentuximab vedotin can be increased when it is combined with Lumacaftor. |
Lusutrombopag | The serum concentration of Brentuximab vedotin can be increased when it is combined with Lusutrombopag. |
Maftivimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Maftivimab. |
Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Brentuximab vedotin. |
Manidipine | The metabolism of Brentuximab vedotin can be decreased when combined with Manidipine. |
Mannitol | The serum concentration of Brentuximab vedotin can be increased when it is combined with Mannitol. |
Margetuximab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Margetuximab. |
Maribavir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Maribavir. |
Mavacamten | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Mavacamten. |
Measles virus vaccine | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Brentuximab vedotin. |
Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Brentuximab vedotin. |
Medroxyprogesterone | The metabolism of Brentuximab vedotin can be increased when combined with Medroxyprogesterone acetate. |
Mefloquine | The serum concentration of Brentuximab vedotin can be increased when it is combined with Mefloquine. |
Meloxicam | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Meloxicam. |
Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Brentuximab vedotin. |
Meningococcal | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Brentuximab vedotin. |
Meperidine | The metabolism of Brentuximab vedotin can be decreased when combined with Meperidine. |
Mepivacaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Mepivacaine. |
Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Brentuximab vedotin. |
Meprednisone | The metabolism of Brentuximab vedotin can be increased when combined with Meprednisone. |
Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Brentuximab vedotin. |
Mestranol | Mestranol may increase the thrombogenic activities of Brentuximab vedotin. |
Methadone | The metabolism of Brentuximab vedotin can be decreased when combined with Methadone. |
Methimazole | The metabolism of Brentuximab vedotin can be decreased when combined with Methimazole. |
Methotrexate | The metabolism of Methotrexate can be decreased when combined with Brentuximab vedotin. |
Methoxy polyethylene | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brentuximab vedotin. |
Methylene blue | The serum concentration of Brentuximab vedotin can be increased when it is combined with Methylene blue. |
Methylergometrine | The metabolism of Brentuximab vedotin can be decreased when combined with Methylergometrine. |
Methylphenobarbital | The metabolism of Brentuximab vedotin can be increased when combined with Methylphenobarbital. |
Methylprednisolone | The metabolism of Brentuximab vedotin can be increased when combined with Methylprednisolone. |
Methylprednisone | The metabolism of Brentuximab vedotin can be decreased when combined with Methylprednisone. |
Methysergide | The metabolism of Brentuximab vedotin can be decreased when combined with Methysergide. |
Metreleptin | The metabolism of Brentuximab vedotin can be increased when combined with Metreleptin. |
Metronidazole | The metabolism of Brentuximab vedotin can be decreased when combined with Metronidazole. |
Metyrapone | The metabolism of Brentuximab vedotin can be increased when combined with Metyrapone. |
Miconazole | The metabolism of Brentuximab vedotin can be decreased when combined with Miconazole. |
Pimozide | The metabolism of Pimozide can be decreased when combined with Brentuximab vedotin. |
Piperaquine | The metabolism of Brentuximab vedotin can be decreased when combined with Piperaquine. |
Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Brentuximab vedotin. |
Pitolisant | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Pitolisant. |
Polatuzumab vedotin | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Polatuzumab vedotin. |
Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Brentuximab vedotin. |
Pomalidomide | The metabolism of Pomalidomide can be decreased when combined with Brentuximab vedotin. |
Ponatinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ponatinib. |
Ponesimod | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ponesimod. |
Posaconazole | The metabolism of Brentuximab vedotin can be decreased when combined with Posaconazole. |
Pralatrexate | The risk or severity of adverse effects can be increased when Pralatrexate is combined with Brentuximab vedotin. |
Pralsetinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Pralsetinib. |
Pramocaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Pramocaine. |
Pravastatin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin. |
Prednisolone | The metabolism of Brentuximab vedotin can be increased when combined with Prednisolone. |
Prednisolone acetate | The metabolism of Brentuximab vedotin can be increased when combined with Prednisolone acetate. |
Prednisolone phosphate | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Prednisolone phosphate. |
Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Brentuximab vedotin. |
Prednisone acetate | The metabolism of Brentuximab vedotin can be increased when combined with Prednisone acetate. |
Pretomanid | The metabolism of Brentuximab vedotin can be decreased when combined with Pretomanid. |
Prilocaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Prilocaine. |
Primaquine | The metabolism of Brentuximab vedotin can be decreased when combined with Primaquine. |
Primidone | The metabolism of Brentuximab vedotin can be increased when combined with Primidone. |
Probenecid | The metabolism of Brentuximab vedotin can be increased when combined with Probenecid. |
Procaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Procaine. |
Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Brentuximab vedotin. |
Propafenone | The serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone. |
Proparacaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Proparacaine. |
Propofol | The metabolism of Brentuximab vedotin can be decreased when combined with Propofol. |
Propoxycaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Propoxycaine. |
Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Brentuximab vedotin. |
Prucalopride | The metabolism of Prucalopride can be decreased when combined with Brentuximab vedotin. |
Quinestrol | Quinestrol may increase the thrombogenic activities of Brentuximab vedotin. |
Quinidine | The serum concentration of Brentuximab vedotin can be increased when it is combined with Quinidine. |
Quinine | The serum concentration of Brentuximab vedotin can be increased when it is combined with Quinine. |
Quinupristin | The metabolism of Brentuximab vedotin can be decreased when combined with Quinupristin. |
immune globulin, | The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Brentuximab vedotin. |
Rabies virus inactivated | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Brentuximab vedotin. |
Rabies virus inactivated | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Brentuximab vedotin. |
Raloxifene | The metabolism of Brentuximab vedotin can be decreased when combined with Raloxifene. |
Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Brentuximab vedotin. |
Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Brentuximab vedotin. |
Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Brentuximab vedotin. |
Ranolazine | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ranolazine. |
Ravulizumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ravulizumab. |
Raxibacumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Raxibacumab. |
Regorafenib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Regorafenib. |
Relugolix | The serum concentration of Brentuximab vedotin can be increased when it is combined with Relugolix. |
Remdesivir | The metabolism of Brentuximab vedotin can be decreased when combined with Remdesivir. |
Reserpine | The serum concentration of Brentuximab vedotin can be increased when it is combined with Reserpine. |
Reslizumab | The risk or severity of adverse effects can be increased when Reslizumab is combined with Brentuximab vedotin. |
Retapamulin | The metabolism of Retapamulin can be decreased when combined with Brentuximab vedotin. |
Revefenacin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Revefenacin. |
Ribociclib | The metabolism of Brentuximab vedotin can be decreased when combined with Ribociclib. |
Rifabutin | The metabolism of Brentuximab vedotin can be increased when combined with Rifabutin. |
Rifampicin | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifampicin. |
Rifamycin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Rifamycin. |
Rifapentine | The metabolism of Brentuximab vedotin can be increased when combined with Rifapentine. |
Rilonacept | The metabolism of Brentuximab vedotin can be increased when combined with Rilonacept. |
Rilpivirine | The metabolism of Brentuximab vedotin can be decreased when combined with Rilpivirine. |
Rimegepant | The serum concentration of Brentuximab vedotin can be increased when it is combined with Rimegepant. |
Riociguat | The serum concentration of Brentuximab vedotin can be increased when it is combined with Riociguat. |
Ripretinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ripretinib. |
Risankizumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Risankizumab. |
Ritonavir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ritonavir. |
Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Brentuximab vedotin. |
Rivaroxaban | The serum concentration of Brentuximab vedotin can be increased when it is combined with Rivaroxaban. |
Rofecoxib | The metabolism of Brentuximab vedotin can be increased when combined with Rofecoxib. |
Roflumilast | The serum concentration of Roflumilast can be increased when it is combined with Brentuximab vedotin. |
Rolapitant | The serum concentration of Brentuximab vedotin can be increased when it is combined with Rolapitant. |
Romidepsin | The metabolism of Romidepsin can be decreased when combined with Brentuximab vedotin. |
Romosozumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Romosozumab. |
Ropeginterferon | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ropeginterferon alfa-2b. |
Ropivacaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Ropivacaine. |
Rosuvastatin | The metabolism of Brentuximab vedotin can be decreased when combined with Rosuvastatin. |
Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Brentuximab vedotin. |
Roxithromycin | The metabolism of Brentuximab vedotin can be decreased when combined with Roxithromycin. |
Rubella virus vaccine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Brentuximab vedotin. |
Rucaparib | The metabolism of Brentuximab vedotin can be decreased when combined with Rucaparib. |
Rufinamide | The metabolism of Brentuximab vedotin can be increased when combined with Rufinamide. |
Ruxolitinib | The metabolism of Ruxolitinib can be decreased when combined with Brentuximab vedotin. |
Sacituzumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sacituzumab govitecan. |
Sapropterin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Sapropterin. |
Saquinavir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Saquinavir. |
Sarecycline | The serum concentration of Brentuximab vedotin can be increased when it is combined with Sarecycline. |
Sarilumab | The metabolism of Brentuximab vedotin can be increased when combined with Sarilumab. |
Satralizumab | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Satralizumab. |
Secobarbital | The metabolism of Brentuximab vedotin can be increased when combined with Secobarbital. |
Secukinumab | The metabolism of Brentuximab vedotin can be increased when combined with Secukinumab. |
Selexipag | The serum concentration of Brentuximab vedotin can be increased when it is combined with Selexipag. |
Selumetinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Selumetinib. |
Sildenafil | The serum concentration of Brentuximab vedotin can be increased when it is combined with Sildenafil. |
Silodosin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Silodosin. |
Siltuximab | The metabolism of Brentuximab vedotin can be increased when combined with Siltuximab. |
Simeprevir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Simeprevir. |
Simvastatin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Simvastatin. |
Siponimod | The metabolism of Siponimod can be decreased when combined with Brentuximab vedotin. |
Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brentuximab vedotin. |
Sirolimus | The metabolism of Sirolimus can be decreased when combined with Brentuximab vedotin. |
Sitagliptin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Sitagliptin. |
Somatostatin | The metabolism of Brentuximab vedotin can be decreased when combined with Somatostatin. |
Somatrogon | The metabolism of Brentuximab vedotin can be increased when combined with Somatrogon. |
Sonidegib | The metabolism of Sonidegib can be decreased when combined with Brentuximab vedotin. |
Sorafenib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Sorafenib. |
Sotagliflozin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Sotagliflozin. |
Sotorasib | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Sotorasib. |
Sotrovimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sotrovimab. |
Spesolimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Spesolimab. |
St. John’s Wort | The serum concentration of Brentuximab vedotin can be decreased when it is combined with St. John’s Wort. |
Stiripentol | The metabolism of Brentuximab vedotin can be decreased when combined with Stiripentol. |
Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Brentuximab vedotin. |
Sulesomab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sulesomab. |
Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Brentuximab vedotin. |
Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Brentuximab vedotin. |
Sulfinpyrazone | The metabolism of Brentuximab vedotin can be increased when combined with Sulfinpyrazone. |
Sunitinib | The metabolism of Sunitinib can be decreased when combined with Brentuximab vedotin. |
Sutimlimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sutimlimab. |
Suvorexant | The serum concentration of Brentuximab vedotin can be increased when it is combined with Suvorexant. |
Synthetic Conjugated | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Brentuximab vedotin. |
Synthetic Conjugated | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Brentuximab vedotin. |
Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Brentuximab vedotin. |
Tafasitamab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tafasitamab. |
Talazoparib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Talazoparib. |
Tamoxifen | The serum concentration of Brentuximab vedotin can be increased when it is combined with Tamoxifen. |
Tasimelteon | The metabolism of Brentuximab vedotin can be decreased when combined with Tasimelteon. |
Tazemetostat | The metabolism of Brentuximab vedotin can be decreased when combined with Tazemetostat. |
Technetium | The serum concentration of Brentuximab vedotin can be increased when it is combined with Technetium Tc-99m sestamibi. |
Tecovirimat | The metabolism of Brentuximab vedotin can be increased when combined with Tecovirimat. |
Tegaserod | The serum concentration of Brentuximab vedotin can be increased when it is combined with Tegaserod. |
Telaprevir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Telaprevir. |
Telithromycin | The metabolism of Brentuximab vedotin can be decreased when combined with Telithromycin. |
Telotristat ethyl | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Telotristat ethyl. |
Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Brentuximab vedotin. |
Temsirolimus | The serum concentration of Brentuximab vedotin can be increased when it is combined with Temsirolimus. |
Teniposide | The metabolism of Brentuximab vedotin can be decreased when combined with Teniposide. |
Tenofovir | The metabolism of Brentuximab vedotin can be decreased when combined with Tenofovir alafenamide. |
Tenofovir disoproxil | The serum concentration of Brentuximab vedotin can be increased when it is combined with Tenofovir disoproxil. |
Tepotinib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Tepotinib. |
Teprotumumab | The risk or severity of adverse effects can be increased when Teprotumumab is combined with Brentuximab vedotin. |
Terbinafine | The metabolism of Brentuximab vedotin can be increased when combined with Terbinafine. |
Terfenadine | The metabolism of Brentuximab vedotin can be decreased when combined with Terfenadine. |
Teriflunomide | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Teriflunomide. |
Testosterone | The metabolism of Brentuximab vedotin can be increased when combined with Testosterone. |
Tetanus immune | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tetanus immune globulin, human. |
Tetracaine | The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Tetracaine. |
Tetracycline | The metabolism of Brentuximab vedotin can be decreased when combined with Tetracycline. |
Tezacaftor | The serum concentration of Brentuximab vedotin can be increased when it is combined with Tezacaftor. |
Tezepelumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tezepelumab. |
Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Brentuximab vedotin. |
Theophylline | The metabolism of Theophylline can be decreased when combined with Brentuximab vedotin. |
Thiamylal | The metabolism of Brentuximab vedotin can be increased when combined with Thiamylal. |
Thiotepa | The metabolism of Thiotepa can be decreased when combined with Brentuximab vedotin. |
Tibolone | Tibolone may increase the thrombogenic activities of Brentuximab vedotin. |
Ticagrelor | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ticagrelor. |
Tick-borne encephalitis | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Brentuximab vedotin. |
Tildrakizumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tildrakizumab. |
Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Brentuximab vedotin. |
Tipranavir | The serum concentration of Brentuximab vedotin can be increased when it is combined with Tipranavir. |
Tisotumab vedotin | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tisotumab vedotin. |
Tivozanib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Tivozanib. |
Tixagevimab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tixagevimab. |
Tixocortol | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tixocortol. |
Tocilizumab | The metabolism of Brentuximab vedotin can be increased when combined with Tocilizumab. |
Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with Brentuximab vedotin. |
Tolvaptan | The metabolism of Tolvaptan can be decreased when combined with Brentuximab vedotin. |
Topiramate | The metabolism of Brentuximab vedotin can be increased when combined with Topiramate. |
Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Brentuximab vedotin. |
Toremifene | The serum concentration of Brentuximab vedotin can be increased when it is combined with Toremifene. |
Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Brentuximab vedotin. |
Trabectedin | The metabolism of Trabectedin can be decreased when combined with Brentuximab vedotin. |
Tralokinumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tralokinumab. |
Tramadol | The metabolism of Tramadol can be decreased when combined with Brentuximab vedotin. |
Trastuzumab | Trastuzumab may increase the neutropenic activities of Brentuximab vedotin. |
Trastuzumab deruxtecan | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Trastuzumab deruxtecan. |
Trastuzumab emtansine | The metabolism of Trastuzumab emtansine can be decreased when combined with Brentuximab vedotin. |
Trazodone | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone. |
Tremelimumab | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tremelimumab. |
Tretinoin | The risk or severity of adverse effects can be increased when Tretinoin is combined with Brentuximab vedotin. |
Triamcinolone | The metabolism of Brentuximab vedotin can be increased when combined with Triamcinolone. |
Triclabendazole | The metabolism of Brentuximab vedotin can be decreased when combined with Triclabendazole. |
Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Brentuximab vedotin. |
Trilaciclib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Trilaciclib. |
Trilostane | The risk or severity of adverse effects can be increased when Trilostane is combined with Brentuximab vedotin. |
Troglitazone | The metabolism of Brentuximab vedotin can be increased when combined with Troglitazone. |
Troleandomycin | The metabolism of Brentuximab vedotin can be decreased when combined with Troleandomycin. |
Tucatinib | The metabolism of Tucatinib can be decreased when combined with Brentuximab vedotin. |
Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Brentuximab vedotin. |
Typhoid Vaccine Live | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Brentuximab vedotin. |
Typhoid Vi | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Brentuximab vedotin. |
Ubrogepant | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ubrogepant. |
Umbralisib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Umbralisib. |
Umeclidinium | The serum concentration of Brentuximab vedotin can be increased when it is combined with Umeclidinium. |
Upadacitinib | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Upadacitinib. |
Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Brentuximab vedotin. |
Valproic acid | The metabolism of Brentuximab vedotin can be decreased when combined with Valproic acid. |
Vandetanib | The serum concentration of Brentuximab vedotin can be increased when it is combined with Vandetanib. |
Vardenafil | The metabolism of Vardenafil can be decreased when combined with Brentuximab vedotin. |
Pregnancy and Lactation
Pregnancy
May cause fetal harm.
Lactation
Not known whether distributed into milk. Effects on nursing infants and on milk production also unknown. Discontinue nursing.
How should this medicine be used?
Brentuximab vedotin injection comes as a powder to be mixed with fluid and injected over 30 minutes intravenously (into a vein) by a doctor or nurse in a medical office or hospital. When brentuximab vedotin is given to treat Hodgkin’s lymphoma, sALCL, or PTCL, it is usually injected once every 3 weeks for as long as your doctor recommends that you receive treatment. When brentuximab vedotin is used in combination with chemotherapy to treat Hodgkin lymphoma as a first treatment, it is usually injected once every 2 weeks for as long as your doctor recommends that you receive treatment.
Brentuximab vedotin injection may cause serious allergic reactions, which usually occur during the infusion of the medication or within 24 hours of receiving a dose. You may receive certain medications before your infusion to prevent an allergic reaction if you had a reaction with previous treatment. Your doctor will watch you carefully while you are receiving brentuximab vedotin. If you experience any of the following symptoms, tell your doctor immediately: fever, chills, rash, hives, itching, or difficulty breathing.
Your doctor may need to delay your treatment, adjust your dose, or stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with brentuximab vedotin injection.
Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before receiving brentuximab vedotin injection,
- tell your doctor and pharmacist if you are allergic to brentuximab vedotin, any other medications, or any of the ingredients in brentuximab vedotin injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor if you are receiving bleomycin. Your doctor will probably tell you not to use brentuximab vedotin injection if you are receiving this medication.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in PrevPac), indinavir (Crixivan), itraconazole (Sporanox), ketoconazole, nefazodone, nelfinavir (Viracept), rifampin (Rifadin, Rimactane, in Rifamate, in Rifater), and ritonavir (Norvir, in Kaletra). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had liver or kidney disease.
- tell your doctor if you are pregnant or plan to become pregnant. If you are a woman who is able to become pregnant, you must take a pregnancy test before starting treatment and use effective birth control during your treatment and for 6 months after your final dose. If you are male with a female partner who is pregnant or could become pregnant, you must use effective birth control during your treatment and for 6 months after your final dose. Talk to your doctor about birth control methods that you can use. If you or your partner become pregnant while receiving brentuximab vedotin injection, call your doctor immediately. Brentuximab vedotin injection may harm the fetus.
- tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving brentuximab vedotin injection.
- you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of receiving brentuximab vedotin injection.
References